Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Purpose Peptide receptor radionuclide therapy (PRRT) is mostly administered using a fixed injected activity (IA) per cycle. This empiric regime results in highly variable absorbed doses to the critical organs and undertreatment of the majority of patients. We conceived a personalized PRRT protocol in which the IA is adjusted to deliver a prescribed absorbed dose to the kidney, with the aim to safely increase tumour irradiation. We herein report on the initial results of our prospective study of personalized PRRT, the P-PRRT Trial (NCT02754297). Methods PRRT-naïve patients with progressive and/or symptomatic neuroendocrine tumour (NET) were scheduled to receive a four-cycle induction course of 177 Lu-octreotate with quantitative SPECT/CT-based dosimetry. The IA was personalized according to the glomerular filtration rate and the body surface area for the first cycle, and according to the prior renal Gy/GBq for the subsequent cycles. The prescribed renal absorbed dose of 23 Gy was reduced by 25-50% in case of significant renal or haematological impairment. Responders were allowed to receive consolidation or maintenance cycles, for each of which 6 Gy to the kidney were prescribed. We simulated the empiric PRRT regime by fixing the IA at 7.4 GBq per cycle, with the same percentage reductions as above. Radiological, molecular imaging, biochemical, and quality of life responses, as well as safety, were assessed. Results Fifty-two patients underwent 171 cycles. In 34 patients who co…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These studies have demonstrated wide interpatient variability of renal absorbed dose by a factor of 10, underscoring the importance of dosimetry.”
From Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns (2021) · cites this paper as [61]
Citations
Cites
Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors
Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., Mittra, E., Kunz, P. L., Kulke, M. H., Jacene, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1607427 · Cited by 3,308
Interpreting the significance of changes in health-related quality-of-life scores.
Osoba, D., Rodrigues, G., Myles, J., Zee, B., & Pater, J. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.139 · Cited by 2,961
Kwekkeboom, D. J., de Herder, W. W., Kam, B. L., van Eijck, C. H., van Essen, M., Kooij, P. P., Feelders, R. A., van Aken, M. O., & Krenning, E. P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.2553 · Cited by 1,456
Quality of life research within the EORTC—the EORTC QLQ-C30
Fayers, P., & Bottomley, A. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00448-8 · Cited by 924
Bodei, L., Cremonesi, M., Ferrari, M., Pacifici, M., Grana, C. M., Bartolomei, M., Baio, S. M., Sansovini, M., & Paganelli, G. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-008-0778-1 · Cited by 428
Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study
Bodei, L., Cremonesi, M., Grana, C. M., Fazio, N., Iodice, S., Baio, S. M., Bartolomei, M., Lombardo, D., Ferrari, M. E., Sansovini, M., et al. (2011) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-1902-1 · Cited by 424
Sandström, M., Garske-Román, U., Granberg, D., Johansson, S., Widström, C., Eriksson, B., Sundin, A., Lundqvist, H., & Lubberink, M. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.107524 · Cited by 287
Wild, D., Fani, M., Fischer, R., Del Pozzo, L., Kaul, F., Krebs, S., Fischer, R., Rivier, J. E. F., Reubi, J. C., Maecke, H. R., et al. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.138834 · Cited by 266
Dose Mapping After Endoradiotherapy with 177Lu-DOTATATE/DOTATOC by a Single Measurement After 4 Days
Hänscheid, H., Lapa, C., Buck, A. K., Lassmann, M., & Werner, R. A. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.193706 · Cited by 219
Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry
Sundlöv, A., Sjögreen-Gleisner, K., Svensson, J., Ljungberg, M., Olsson, T., Bernhardt, P., & Tennvall, J. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3678-4 · Cited by 209
Cited by
Items 101–184 of 184
Mader, N., Schoeler, C., Pezeshkpour, N., Klimek, K., Groener, D., Happel, C., Tselis, N., Mandel, P. C., Grünwald, F., & Sabet, A. (2023) · Cancers · doi:10.3390/cancers15184605 · Cited by 9
Peptide Receptor Radionuclide Therapy During the COVID-19 Pandemic: Are There Any Concerns?
Bodei, L., Bergsland, E. K., de Herder, W. W., Ferone, D., Hicks, R. J., Hope, T. A., Kunikowska, J., Pavel, M., Reidy‐Lagunes, D. L., Siveke, J. T., et al. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.249136 · Cited by 8
“Grade 3–4 lymphopenia occurs in 75% of patients treated with 90Y-DOTATOC (2) and in 18%–52% of patients treated with 177Lu-DOTATATE (3,4), with an early nadir 15 d after therapy and subsequent slow partial recovery.”
BackgroundRitt, P., Jobic, C., Beck, M., Schmidkonz, C., Kuwert, T., Uder, M., & Brand, M. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.243782 · Cited by 8
“There is an indication that personalized, dosimetry-based dosing could lead to increased tumor doses (24) and better response rates (25).”
BackgroundAnatomy-based correction of kidney PVE on $$^{177}\text{Lu}$$ SPECT images
Salvadori, J., Allegrini, O., Opsommer, T., Carullo, J., Sarrut, D., Porot, C., Ritzenthaler, F., Meyer, P., & Namer, I. J. (2024) · EJNMMI Physics · doi:10.1186/s40658-024-00612-8 · Cited by 12
“As a result, significant efforts have been directed toward personalized dosimetry to individualize PRRT. Ongoing con - trolled clinical trials aim to demonstrate the superiority of dosimetry-based PRRT over standard dose regimens [15, 16].”
BackgroundImpact of treatment on quality of life in neuroendocrine neoplasm survivors
Modica, R., Benevento, E., Salvia, A. L., Mazzilli, R., Pandozzi, C., Pecora, G., Barrea, L., Colao, A. A. L., Faggiano, A., & on behalf of NIKE Group (2025) · Endocrine Related Cancer · doi:10.1530/erc-24-0303 · Cited by 9
Dosimetry of nuclear medicine therapies: current controversies and impact on treatment optimization
Cicone, F., Gnesin, S., & Cremonesi, M. (2021) · The Quarterly Journal of Nuclear Medicine and Molecular Imaging · doi:10.23736/s1824-4785.21.03418-x · Cited by 7
Optimisation of radioligand therapy in neuroendocrine tumours: Current and evolving evidence
Navalkissoor, S., Gnanasegaran, G., & Grossman, A. B. (2022) · Journal of Neuroendocrinology · doi:10.1111/jne.13208 · Cited by 9
“PRRT (P-PRRT), treated patients with a prescribed renal dose of 23 Gy.(35) In 34 of there treated patients, the median cumulative administered activity was 36.”
MethodInfluentialSiebinga, H., der Veen, B. J. D. W., Beijnen, J. H., Stokkel, M. P. M., Dorlo, T. P. C., Huitema, A. D. R., & Hendrikx, J. J. M. A. (2023) · EJNMMI Physics · doi:10.1186/s40658-023-00565-4 · Cited by 7
Zamanian, A., Rousseau, É., Buteau, F.-A., Arsenault, F., Beaulieu, A., April, G., Juneau, D., Plouznikoff, N., Turcotte, É. E., Allard, C., et al. (2025) · Cancer Imaging · doi:10.1186/s40644-025-00910-z · Cited by 8
“Our initial results, using a renal dosimetry-based regime of peptide receptor radio-nuclide therapy with 177 Lu-DOTATATE, showed that it is possible to safely escalate administered activity and tumour absorbed dose in most patients, including those with larger tumour burden [22].”
Self-citationDesy, A., Bouvet, G. F., Lafrenière, N., Zamanian, A., Després, P., & Beauregard, J. (2022) · EJNMMI Physics · doi:10.1186/s40658-022-00484-w · Cited by 6
“This allowed to determine the area under the time–activity concentration curve and to deduce the self-absorbed dose for each tissue using the activity concentration dose factor [2].”
BackgroundMethodResultSelf-citationSomatostatin receptor‐linked α‐particle therapy in neuroendocrine tumours
Navalkissoor, S., & Grossman, A. B. (2024) · Journal of Neuroendocrinology · doi:10.1111/jne.13463 · Cited by 8
“…in an attempt to improve on the effectiveness of PRRT 13 : some of these strategies include using dosimetry to ensure adequate tumour dosing, 14,15 combining 177 Lu-and 90 Y-PRRT to target both small and large tumours, 16 using chemotherapy as a PRRT radiosensitiser, 17 using a somatostatin…”
Particle filter de-noising of voxel-specific time-activity-curves in personalized 177 Lu therapy
Götz, T. I., Lang, E. W., Schmidkonz, C., Maier, A., Kuwert, T., & Ritt, P. (2019) · Zeitschrift für Medizinische Physik · doi:10.1016/j.zemedi.2019.10.005 · Cited by 5
Targeted radionuclide therapy in endocrine-related cancers: advances in the last decade
Al‐Toubah, T., Strosberg, J., Johnson, J. E. H., & El-Haddad, G. E. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1187870 · Cited by 6
Navalkissoor, S., Toumpanakis, C., Caplin, M. E., & Gnanasegaran, G. (2022) · Journal of Neuroendocrinology · doi:10.1111/jne.13088 · Cited by 5
Siebinga, H., Hendrikx, J. J. M. A., de Vries–Huizing, D. M. V., Huitema, A. D. R., & der Veen, B. J. D. W. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06463-2 · Cited by 5
Moraitis, A., Jentzen, W., Costa, P. F., Kersting, D., Himmen, S., Coelho, M. C., Meckel, M., van Echteld, C. J. A., Fendler, W. P., Herrmann, K., et al. (2024) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.266619 · Cited by 5
“Promising activity escalation strategies, such as the P-PRRT trial, could achieve response rates of 59% at the cost of subacute grade 3 or 4 lymphocytopenia in 52% of patients ( 37 ).”
BackgroundAkhavanallaf, A., Lu, Z., Peterson, A., Blakkisrud, J., Kurkowska, S., Yadav, S., Wang, C., Uribe, C., Stokke, C., Rahmim, A., et al. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.269098 · Cited by 11
Self-citationResch, S., & Delker, A. (2026) · Zeitschrift für Medizinische Physik · doi:10.1016/j.zemedi.2026.03.011 · Cited by 5
Ferrara, R., Zemmour, C., Reichert, T., Ouk, D., Niccoli, P., Maniry-Quellier, J., Brenot-Rossi, I., Charrier, N., & Oziel-Taïeb, S. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1568243 · Cited by 6
Golzaryan, A., Souri, M., Kashkooli, F. M., Rahmim, A., & Soltani, M. (2025) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1013247 · Cited by 5
“Their effectiveness lies in the ability to deliver targeted radiation directly to cancerous cells, minimizing damage to healthy tissue [132].”
Miyaji, N., Miwa, K., Akiya, N., Wachi, K., Komatsu, A., Masubuchi, M., Yamashita, K., Wagatsuma, K., Yamao, T., Yagihashi, T., et al. (2025) · Health and Technology · doi:10.1007/s12553-025-01009-y · Cited by 4
Malandrino, P., Mazzilli, R., Puliani, G., Molfetta, S. D., Pugliese, G., Olana, S., Colao, A. M. L., Faggiano, A., & on behalf of the NIKE Group (2022) · Cancers · doi:10.3390/cancers15010115 · Cited by 4
Dubois, J., Tosato, G., Garrigue, P., Taïeb, D., Guillet, B. A., & Nail, V. (2024) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2023.0195 · Cited by 4
Dia, A. D., Ferrari, M. E., Travaini, L. L., Grappeja, L., Guglielmo, P., Barone, A. A., Mei, R., Papi, S., Ceci, F., & Grana, C. M. (2025) · Clinical and Translational Imaging · doi:10.1007/s40336-025-00685-0 · Cited by 4
Beykan, S., Tran‐Gia, J., Jensen, S. B., & Laßmann, M. (2022) · Physica Medica · doi:10.1016/j.ejmp.2022.06.002 · Cited by 4
“[1] (with 52 patients) published their SPECT/CT based dosimetry studies and showed that the suggested 4 × 7.”
BackgroundRadiobiology and Radiation Dosimetry in Nuclear Medicine
Salvatori, M., Cremonesi, M., Indovina, L., Chianelli, M., Pacilio, M., Danieli, R., Chiesa, C., & ZANZONICO, P. B. (2022) · Springer eBooks · doi:10.1007/978-3-031-05494-5_6 · Cited by 5
Khan, J., Rydèn, T., van Essen, M., Svensson, J., & Bernhardt, P. (2025) · EJNMMI Physics · doi:10.1186/s40658-025-00769-w · Cited by 5
Yang, H., Qi, M., Chen, Z., Liu, F., Xu, J., Xu, X., Kong, Q., Zhang, J., & Song, S. (2025) · Medical Physics · doi:10.1002/mp.17852 · Cited by 3
Barakat, A., Santoro, L., Vivien, M., Kotzki, P., Deshayes, E., & Khier, S. (2023) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-023-00829-5 · Cited by 3
Telo, S., Filice, A., Versari, A., Lamberti, G., Campana, D., Calabrò, D., Fanti, S., & Ambrosini, V. (2021) · Clinical and Translational Imaging · doi:10.1007/s40336-021-00443-y · Cited by 3
Vallot, D., Brillouet, S., Pondard, S., Vija, L., Texier, J., Dierickx, L., & Courbon, F. (2024) · EJNMMI Physics · doi:10.1186/s40658-024-00615-5 · Cited by 3
Zhu, W., Liu, M., & Huo, L. (2023) · Journal of Pancreatology · doi:10.1097/jp9.0000000000000122 · Cited by 4
“…[174] 2018 100/0/0 Prospective 49/200** RECIST 45 94 27 42 Demirci [175] 2018 100/0/0 Retrospective 62/186 RECIST 61 69 42 57 Del Prete [176] 2019 100/0/0 Prospective 13/39 RECIST 77 92 NA NA Aalbersberg [177] 2019 ( 177 Lu or 90 Y or both), cycles of treatment, dose administered,…”
Frontiers in radiopharmaceuticals for neuroendocrine tumors
Puranik, A. D., Dev, I. D., & Prasad, V. (2025) · Journal of Neuroendocrinology · doi:10.1111/jne.70006 · Cited by 2
Nilica, B., Svirydenka, A., Fritz, J., Bayerschmidt, S., Kroiss, A. S., Gruber, L. N., & Virgolini, I. J. (2021) · Revista Española de Medicina Nuclear e Imagen Molecular · doi:10.1016/j.remn.2021.03.004 · Cited by 3
Taïeb, D., Deandreis, D., & Hicks, R. J. (2024) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268136 · Cited by 2
“…prediction of radiation dose delivery, or at least veri fi cation of radiation dose delivery by posttreatment imaging, becomes important to understanding the likelihood of response and potentially modifying treat-ment planning — ideally before, or at least during, the course of treatment ( 9 ).”
Staanum, P. F., & Iversen, P. (2025) · EJNMMI Physics · doi:10.1186/s40658-025-00772-1 · Cited by 1
S-values for bone marrow dosimetry in preclinical radiopharmaceutical studies with rodents
Obaid, M., Rahmim, A., Segars, W. P., Brosch-Lenz, J., & Uribe, C. (2025) · EJNMMI Physics · doi:10.1186/s40658-025-00752-5 · Cited by 3
Penninckx, S., Delbart, W., Mileva, M., Kassas, M., Levillain, H., Artigas, C., Flamen, P., & Karfis, I. (2026) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.271564 · Cited by 1
“Nonetheless, these thresholds may be overly conservative, as evidence suggests that they can be exceeded with manageable toxicity ( 25 – 29 ).”
Are Radiopharmaceutical Therapy Trials Designed to Undertreat?
Bertolet, A. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-26-00796 · Cited by 1
Bakr, H., Al-Awar, A., Spetz, J. K. E., & Forssell-Aronsson, E. B. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27198709 · Cited by 1
Walrand, S., & Hesse, M. (2021) · Springer eBooks · doi:10.1007/978-3-030-65850-2_3 · Cited by 1
Radiobiology and Radiation Dosimetry in Nuclear Medicine
Salvatori, M., Cremonesi, M., Indovina, L., Chianelli, M., Pacilio, M., Danieli, R., Chiesa, C., & ZANZONICO, P. B. (2022) · Springer eBooks · doi:10.1007/978-3-319-26067-9_6-2 · Cited by 2
Barquero, R., Velasco, J., Andres, C., Torres, R., & Ruano, R. (2022) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2022.110459 · Cited by 1
Ünal, Ç., Selcuk, N. A., Biricik, F. S., Alan, Ö., Ordu, Ç., Selvi, O., Sakin, A., Sever, N., Topcu, Z. A., Akyıldız, A., et al. (2023) · Eurasian Journal of Medicine and Oncology · doi:10.14744/ejmo.2023.48337 · Cited by 1
“0%.[21] Furthermore, the prospective phase I-II IDEO trial revealed an ORR of 29.”
Gabiña, P. M., Vela, N. C., Rosales, L. I., Martí-Climent, J. M., Gómez, L. C. M., Fuentes, T., Fuentes, C. M., Uruen, A. M., & Sanz, R. B. (2024) · Revista de Física Médica · doi:10.37004/sefm/2024.25.2.003 · Cited by 1
Neuroendocrine Tumors: Therapy with Radiolabeled Peptides
Bodei, L., Jayaprakasam, V. S., Kidd, M. S., Gilardi, L., Volterrani, D., Paganelli, G., Grana, C. M., & Modlin, I. M. (2022) · Springer eBooks · doi:10.1007/978-3-319-26067-9_50-3 · Cited by 1
Nuclear Imaging and Therapy: Towards a Personalized Approach in HCC and NET
Veenstra, E. B. (2023) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.749428332 · Cited by 1
La dosimétrie est-elle vraiment utile pour la radiothérapie interne vectorisée ?
Vuillez, J.-P. (2020) · Médecine Nucléaire · doi:10.1016/j.mednuc.2020.01.001
Spicing up prostate cancer theranostics
van Kalmthout, L. W. M. (2020) · Utrecht University Repository (Utrecht University) · doi:10.33540/334
Therapiekonzepte bei fernmetastasierten GEP-NEN – medikamentöse und interventionelle Therapie
Frilling, A., & Clift, A. K. (2021) · Springer Reference Medizin · doi:10.1007/978-3-662-61724-3_52-1
Is Dosimetry Necessary in the Treatment of PRRT?
Beykan, S., Toklu, T., & Selçuk, N. A. (2021) · Nuclear Medicine Seminars · doi:10.4274/nts.galenos.2021.0033
Desy, A., Bouvet, G. F., Lafrenière, N., Zamanian, A., Després, P., & Beauregard, J. (2022) · Research Square · doi:10.21203/rs.3.rs-1514915/v1
Self-citationNeuroendocrine Tumors: Therapy with Radiolabeled Peptides
Bodei, L., Jayaprakasam, V. S., Kidd, M. S., Gilardi, L., Volterrani, D., Paganelli, G., Grana, C. M., & Modlin, I. M. (2022) · Springer eBooks · doi:10.1007/978-3-319-26067-9_50-2
Radiobiology and Radiation Dosimetry in Nuclear Medicine
Salvatori, M., Cremonesi, M., Indovina, L., Chianelli, M., Pacilio, M., Danieli, R., Chiesa, C., & ZANZONICO, P. B. (2022) · Springer eBooks · doi:10.1007/978-3-319-26067-9_6-3
Therapiekonzepte bei fernmetastasierten GEP-NEN – medikamentöse und interventionelle Therapie
Frilling, A., & Clift, A. K. (2022) · Springer Reference Medizin · doi:10.1007/978-3-662-63317-5_52
Neuroendocrine Tumors: Therapy with Radiolabeled Peptides
Bodei, L., Jayaprakasam, V. S., Kidd, M. S., Gilardi, L., Volterrani, D., Paganelli, G., Grana, C. M., & Modlin, I. M. (2022) · Springer eBooks · doi:10.1007/978-3-031-05494-5_50
Bedeutung der Dosimetrie bei der Therapie aus Sicht der Medizinischen Physik
Laßmann, M., & Glatting, G. (2023) · Angewandte Nuklearmedizin · doi:10.1055/a-1802-8618
“[33] Del Prete M, Buteau FA, Arsenault F et al.”
BackgroundBarquero, R., Villar, C., Hurtado, A., Andres, C., Ruano, R., & Torres, R. (2023) · Research Square · doi:10.21203/rs.3.rs-2792645/v1
Pharmacometric approaches to improve theranostics
Siebinga, H. (2023) · Utrecht University Repository (Utrecht University) · doi:10.33540/1920
Advances with radiopharmaceutical therapy in cancer
Lepareur, N. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00002-9
Seyedabadi, A., Porouhan, P., Sadoughi, H.-R., & Ghahramani‐Asl, R. (2025) · Radiation Protection Dosimetry · doi:10.1093/rpd/ncaf054 · Cited by 1
Direct Conversion for SPECT Imaging
Iniewski, K. K. (2025) · Springer eBooks · doi:10.1007/978-3-031-94005-7_5
6. Global Trends in Beta-Emitter Radioligand Therapy
Hotta, M. (2025) · Japanese Journal of Radiological Technology · doi:10.6009/jjrt.25-0902
Jóźwik−Plebanek, K., Saracyn, M., Kołodziej, M., Mądra, W., Durma, A. D., Dziuk, M., Balcerska, Z., Janiak, K., Gniadek-Olejniczak, K. A., & Kamiński, G. (2025) · Cancers · doi:10.3390/cancers17193219
Future Trends in NEN Care: QoL and Multidisciplinary Care
Modica, R., Liccardi, A., Benevento, E., & Colao, A. A. L. (2025) · Endocrinology · doi:10.1007/978-3-030-67823-4_18-1
Optimizing 131I-mIBG Dosimetry: Validation of Simplified Time-Point and Segmentation Approaches
Kurkowska, S., Poniatowska, M. E., Uribe, C., Birkenfeld, B., & Piwowarska-Bilska, H. (2025) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-025-00959-5
“A simpler alternative is the sphere method [ 8–10 ], which requires minimal user input compared to full organ segmentation.”
Future Trends in NEN Care: QoL and Multidisciplinary Care
Modica, R., Liccardi, A., Benevento, E., & Colao, A. A. L. (2025) · Endocrinology · doi:10.1007/978-3-031-83281-9_18
Danieli, R., Stella, M., Leube, J., Tran‐Gia, J., Marin, C., Uribe, C., Vanderlinden, B., Reynaert, N., Flamen, P., & Levillain, H. (2024) · Figshare · doi:10.6084/m9.figshare.26628541
Siebinga, H., de Wit-van der Veen, B. J., Beijnen, J. H., Stokkel, M. P. M., Dorlo, T. P. C., Huitema, A. D. R., & Hendrikx, J. J. M. A. (2024) · Figshare · doi:10.6084/m9.figshare.26612495
Vallot, D., Brillouet, S., Pondard, S., Vija, L., Texier, J.-S., Dierickx, L., & Courbon, F. (2024) · Figshare · doi:10.6084/m9.figshare.25530222
Deshayes, E., Assénat, E., Meignant, L., Bardiès, M., Santoro, L., & Gourgou, S. (2023) · Figshare · doi:10.6084/m9.figshare.22605787
Desy, A., Bouvet, G. F., Lafrenière, N., Zamanian, A., Després, P., & Beauregard, J. (2022) · Figshare · doi:10.6084/m9.figshare.20508629
Self-citationDesy, A., Bouvet, G. F., Croteau, É., Lafrenière, N., Turcotte, É. E., Després, P., & Beauregard, J. (2021) · Figshare · doi:10.6084/m9.figshare.16909573
Self-citationFele‐Paranj, A., Saboury, B., Uribe, C., & Rahmim, A. (2024) · Figshare · doi:10.6084/m9.figshare.25045484
Malcolm, J., Falzone, N., Gains, J. E., Aldridge, M. D., Mirando, D. M., Lee, B. Q., Gaze, M. N., & Vallis, K. A. (2022) · Figshare · doi:10.6084/m9.figshare.19445683
47Chapter 3 Integrating AI and digital twin technology in cancer therapy
Malviya, R., Rajput, S., Roy, M., Sridhar, S. B., & Thomas, S. (2025) · De Gruyter eBooks · doi:10.1515/9783111670744-003
Gabiña, P. M., Vela, N. C., Rosales, L. I., Martí-Climent, J. M., Gómez, L. C. M., Fuertes, T. M., Fuentes, C. M., Uruen, A. M., & Sanz, R. B. (2026) · Physica Medica · doi:10.1016/j.ejmp.2026.105752
Deep learning for partial volume correction in SPECT imaging
Kaprélian, T. (2025) · theses.fr (ABES) · doi:10.70675/7fb45775zf8c4z4961z9589z9be8710187f8
Longo, M., Tonini, E., Domenico, G. D., Longo, L., Macis, C., Panzini, I., Uccelli, L., Turra, A., Urso, L., Cittanti, C., et al. (2026) · EJNMMI Research · doi:10.1186/s13550-026-01442-8
Guth, M. A. S. (2026) · Clinical nuclear medicine open. · doi:10.1097/nm9.0000000000000092
Warfvinge, C. F., Kapidzic, S. C., Gustafsson, J., Jessen, L., Svensson, J. B., Sundlöv, A., & Gleisner, K. S. (2026) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.271439 · Cited by 1
Zhang, S., Deng, J., Zhang, N., Bai, X., Li, B., Qi, C., Yang, J., Zhang, Y., & Chen, Y. (2026) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-026-08125-5
“Current treatments for bone-metastatic NENs, including surgery, radiotherapy, somatostatin analogues (SSAs), chemotherapy, and targeted therapy, have inherent limitations [ 7, 8 ].”
New and emerging somatostatin therapies for neuroendocrine tumors: “what is in the pipeline”
Lee, L., Ito, T., & Jensen, R. T. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2735443
Huang, Q., & Huang, G. (2026) · Pharmaceuticals · doi:10.3390/ph19101641
Metadata
- Authors
- Del Prete, M., Buteau, F.-A., Arsenault, F., Saighi, N., Bouchard, L.-O., Beaulieu, A., & Beauregard, J.-M.
- Affiliations
- Université Laval (CA)
- Centre hospitalier universitaire de Québec (CA)
- Corresponding author
- Beauregard, Jean-Mathieu
- Venue
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2018-11-30
- Volume
- 46
- Issue
- 3
- Pages
- 728-742
- ISSN
- 1619-7070 (ISSN-L)
- 1619-7089
- OpenAlex
- W2902656640
- Cited by
- 184
- References
- 26
- Citations by year
- 2026: 12 · 2025: 28 · 2024: 28 · 2023: 34 · 2022: 31 · 2021: 28 · 2020: 13 · 2019: 9 · 2018: 1
- FWCI
- 9.96
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- European Journal of Nuclear Medicine and Molecular Imaging (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research (MOP-142233)
- Fonds de Recherche du Québec - Santé
- Ministère de l'éducation et de l’enseignement supérieur du Québec
- Topics
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- peptide receptor radionuclide therapy, 177Lu-octreotate, personalized dosimetry, glomerular filtration rate, renal dysfunction, neuroendocrine tumors, SPECT/CT dosimetry, treatment response, quality of life, hematologic toxicity
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Female, Humans, Intestinal Neoplasms, Male, Middle Aged, Pancreatic Neoplasms, Radiometry, Safety, Stomach Neoplasms, Receptors, Peptide, Neuroendocrine Tumors, Young Adult, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.